Adverse effects of anticancer agents that target the VEGF pathway

@article{Chen2009AdverseEO,
  title={Adverse effects of anticancer agents that target the VEGF pathway},
  author={Helen X. Chen and Jessica N. Cleck},
  journal={Nature Reviews Clinical Oncology},
  year={2009},
  volume={6},
  pages={465-477}
}
Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an important part of standard therapy in multiple cancer indications. With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair. Although most adverse effects of VEGF inhibitors are… Expand
Pathways mediating VEGF-independent tumor angiogenesis.
  • N. Ferrara
  • Medicine
  • Cytokine & growth factor reviews
  • 2010
TLDR
The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies. Expand
VEGF Inhibition, Hypertension, and Renal Toxicity
TLDR
These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure. Expand
Dopamine is a safe antiangiogenic drug which can also prevent 5‐fluorouracil induced neutropenia
TLDR
The results indicate that DA may be safely used as an antiangiogenic drug for the treatment of malignant tumors and prevented 5‐fluorouracil induced neutropenia in HT29 colon cancer bearing mice. Expand
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
TLDR
The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies. Expand
The VEGF family in cancer and antibody-based strategies for their inhibition
TLDR
This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in pre-clinical and clinical studies. Expand
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
TLDR
The development of rash with tyrosine kinase inhibitors or monoclonal antibodies targeting the epidermal growth factor receptor is associated with superior outcomes in lung, head and neck, colorectal, and pancreatic cancer studies and may be a marker of effective target inhibition. Expand
Chapter 19 Anti-VEGF Therapy in Cancer : A Double-Edged Sword
Vascular endothelial growth factor (VEGF) is a mitogen that plays a crucial role in angiogenesis and lymphangiogenesis. It is involved in tumor survival through inducing tumor angiogenesis and byExpand
Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.
TLDR
A new combination strategy is introduced that links direct antiangiogenic protein and enzyme prodrug system with dual-targeting antiangIogenic and antiproliferative therapeutic effect in tumor microenvironment and has the potential to overcome clinical hindrances. Expand
The role of angiogenesis inhibitors in the management of melanoma.
TLDR
An overview of the importance of angiogenesis in melanoma is presented and draws attention to some of the key molecules that are currently being targeted rationally within clinical studies, including anti-angiogenic and anti-vascular agents and their mechanisms of action. Expand
Anti-VEGF Therapy in Cancer: A Double-Edged Sword
TLDR
Tumor therapies targeting VEGF along with their side effects are presented and, finally, new directions in anti-VEGF therapy are considered along with the challenges. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 102 REFERENCES
VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function.
TLDR
Inhibition of VEGFR2 significantly increases systolic and diastolic blood pressure and reduces the number of microvessels in patients with advanced solid tumours treated with BAY 57-9352, an oral VEGF receptor 2 (VEGFR2) inhibitor. Expand
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
TLDR
There are three US Food and Drug Administration–approved angiogenesis inhibitors for the treatment of cancer that specifically target vascular endothelial growth factor (VEGF) signaling and a plethora of new small-molecule tyrosine kinase inhibitors in preclinical development and early-phase clinical trials that target VEGFR with varying degrees of specificity. Expand
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
  • T. Choueiri
  • Medicine
  • Current opinion in investigational drugs
  • 2008
TLDR
Although frequent side effects have included fatigue, hypertension, diarrhea, hand-foot syndrome and proteinuria, axitinib was well tolerated overall. Expand
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
TLDR
Although axitinib inhibits platelet-derived growth factor receptors and KIT with nanomolar in vitro potencies, based on pharmacokinetic/pharmacodynamic analysis, axitine acts primarily as a VEGFR tyrosine kinase inhibitor at the current clinical exposure. Expand
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
  • S. Wedam, J. Low, +17 authors S. Swain
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Bvacizumab has inhibitory effects on VEGF receptor activation and vascular permeability, and induces apoptosis in tumor cells, and persists with the addition of chemotherapy. Expand
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
  • N. Azad, E. Posadas, +14 authors E. Kohn
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Combination therapy with sorafenib and bevacizumab has promising clinical activity, especially in patients with ovarian cancer, but the rapidity and frequency of sorAFenib dose reductions indicates that sorafanib at 200 mg twice daily with bevacsumab 5 mg/kg every 2 weeks may not be tolerable long term, and alternate sorafinib dosing schedules should be explored. Expand
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
TLDR
Clinical efficacy of antiangiogenic therapy with bevacizumab is being evaluated in several phase 3 trials in various types of cancer, as well as in patients with age-related macular degeneration. Expand
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
TLDR
Axitinib shows clinical activity in patients with cytokine-refractory metastatic renal-cell cancer and these adverse events were generally manageable and controlled by dose modification or supportive care, or both. Expand
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
TLDR
Biochemical findings of thyroid dysfunction in a patient treated with sunitinib for recurrence of gastrointestinal stromal tumor and patient-reported fatigue noted during clinical trials led to the monitoring of serum thyroid-stimulating hormone (TSH) concentrations to rule out primary hypothyroidism. Expand
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
TLDR
Bvacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer, and this trial was stopped after the interim analysis met the criteria for early stopping. Expand
...
1
2
3
4
5
...